|
|
Article: Positive results reported from indiplon modified release 15 mg trial in insomnia.
- Article from:
- Drug Week
- Article date:
- October 1, 2004
CopyrightCOPYRIGHT 2004 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
2004 OCT 1 - (NewsRx.com & NewsRx.net) -- Neurocrine Biosciences, Inc., (NBIX) announced positive efficacy and safety results from the company's phase III clinical trial with indiplon modified release 15 mg in 229 elderly patients with chronic insomnia.
Neurocrine is on track to submit its two New Drug Applications (NDAs) for the immediate and modified release formulations of indiplon beginning in October 2004. The two NDAs will include data from phase I, II, and III clinical trials in over 7400 patients and subjects with over 300,000 patient exposures in one of the most comprehensive clinical programs in insomnia.
To date the indiplon clinical program ...